News Eli Lilly and Company Xetra

Equities

LLY

US5324571083

Real-time Estimate Tradegate Other stock markets 07:56:20 17/07/2024 pm IST			5-day change	1st Jan Change
835.6 ^EUR	-4.20%		-4.47%	+57.42%

03:53pm	TD Cowen Raises Price Target on Eli Lilly to $1,050 From $850	MT
03:38pm	Earnings reports take center stage as tech stocks tumble

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

TD Cowen Raises Price Target on Eli Lilly to $1,050 From $850	07:23pm	MT
Earnings reports take center stage as tech stocks tumble	07:08pm
Wall Street set to fall as megacap chip, tech stocks tumble	06:44pm	RE
ANALYST RECOMMENDATIONS : American Airlines, Chevron, UnitedHealth, Bank of America, Eli Lilly...	02:41pm
Roche reports positive early results in obesity drug trial	11:43am	RE
Aclaris Therapeutics Sells Olumiant Royalties, Milestone Payments From Eli Lilly	17/07	MT
Goldman Sachs Adjusts Price Target on Eli Lilly to $812 From $793	16/07	MT
Novo owner backs Swiss biotech Asceneuron in $100 million round	16/07	RE
Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market	13/07	RE
Ozempic linked with lower dementia risk, nicotine use, British study finds	12/07	RE
EU Drug Regulator Issues New Safety Measures for GLP-1 Drugs Amid Aspiration Risk Concerns	12/07	MT
UBS Raises Price Target on Eli Lilly to $1,100 From $910, Maintains Buy Rating	12/07	MT
Patients on weight-loss drugs should inform doctor before surgery, EU regulator says	12/07	RE
Neuroendocrine Tumors Pipeline 2024 \| Amgen, Eli Lilly and Company, GlaxoSmithKline, Hutchison Medipharma Limited, Ipsen, Seneca Therapeutics, Crinetics Pharmaceuticals, ADC Therapeutics, BeiGene	12/07	AQ
Health Care Up as Obesity-Drug Wars Continue -- Health Care Roundup	12/07	DJ
Pfizer moves forward with once-daily weight loss drug	11/07	RE
JPMorgan Adjusts Price Target on Eli Lilly and Co. to $1,000 From $900, Maintains Overweight Rating	11/07	MT
Morgan Stanley Adjusts Price Target on Eli Lilly and Co. to $1,083 From $1,023, Maintains Overweight Rating	11/07	MT
Berenberg Adjusts Price Target on Eli Lilly & Co. to $1,000 From $850, Maintains Buy Rating	11/07	MT
US Senator Sanders optimistic Novo Nordisk can be pressured to cut Wegovy, Ozempic prices	11/07	RE

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Headlines

David Ricks, CEO of Eli Lilly: A market of over a billion people

March 13, 2024 at 12:17 am IST